Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
330
datasets available to search
ShareScore release 0.7.1
Dataset results
330 results for “non-alcoholic fatty liver disease”
Expression data from human non-alcoholic fatty liver disease stages
GEO Series GSE63067. Homo sapiens. 18 samples. Type: Expression profiling by array.
The imprinted gene Zac1 regulates steatosis in developmental cadmium-induced non-alcoholic fatty liver disease
GEO Series GSE201906. Mus musculus. 48 samples. Type: Expression profiling by high throughput sequencing.
Methylation profiles in non-alcoholic fatty liver disease
GEO Series GSE49542. Homo sapiens. 59 samples. Type: Methylation profiling by genome tiling array.
HEPATIC TRANSCRIPTOME SIGNATURES IN PATIENTS WITH VARYING DEGREES OF NON-ALCOHOLIC FATTY LIVER DISEASE COMPARED TO HEALTHY NORMAL-WEIGHT INDIVIDUALS
GEO Series GSE126848. Homo sapiens. 57 samples. Type: Expression profiling by high throughput sequencing.
Expression data from GNMT and MAT1A knockout models that develop all the stages of non-alcoholic fatty liver disease including hepatocellular carcinoma [GNMT_MAT1A_3&8_months]
GEO Series GSE63027. Mus musculus. 39 samples. Type: Expression profiling by array.
Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity
GEO Series GSE207310. Homo sapiens. 30 samples. Type: Expression profiling by high throughput sequencing.
Expression data from GNMT and MAT1A knockout models that develop all the stages of non-alcoholic fatty liver disease including hepatocellular carcinoma [MAT1A_15months]
GEO Series GSE63062. Mus musculus. 15 samples. Type: Expression profiling by array.
Low carbohydrate diet study for non-alcoholic fatty liver disease patients
GEO Series GSE107650. Homo sapiens. 14 samples. Type: Expression profiling by high throughput sequencing.
Integrated Gut/Liver-on-a-Chip platform as in vitro human model of non-alcoholic fatty liver disease
GEO Series GSE152091. Homo sapiens. 23 samples. Type: Expression profiling by high throughput sequencing.
Data from: Non-invasive stratification of non-alcoholic fatty liver disease by whole-transcriptome cell-free mRNA characterization
<p>Hepatic fibrosis stage is the most important determinant of outcomes in patients with non-alcoholic fatty liver disease (NAFLD). There is an urgent need for non-invasive tests that can accurately stage fibrosis and determine efficacy of interventions. Here we describe a novel cf-mRNA-Sequencing approach that can accurately and reproducibly profile low levels of circulating mRNAs and evaluate the feasibility of developing a cf-mRNA-based NAFLD fibrosis classifier. Using separate discovery and validation cohorts with biopsy-confirmed NAFLD (n=176 and 59, respectively) and healthy subjects (n=23), we performed serum cf-mRNA RNA-Seq profiling. Differential expression analysis identified 2498 dysregulated genes between NAFLD and healthy subjects and 134 fibrosis-associated genes in NAFLD patients. Comparison between cf-mRNA and liver tissues transcripts revealed significant overlap of fibrosis associated genes and pathways indicating that the circulating cf-mRNA transcriptome reflects molecular changes in the livers of NAFLD patients. In particular, metabolic and immune pathways reflective of known underlying steatosis and inflammation were highly dysregulated in the cf-mRNA profile of patients with advanced fibrosis. Finally, we used an elastic net ordinal logistic model to develop a classifier that predicts clinically significant fibrosis (F2-4). In an independent cohort, the cf-mRNA classifier was able to identify 50% of patients with at least 90% probability of clinically significant fibrosis. We demonstrate<b> </b>a<b> </b>novel and robust cf-mRNA-based RNA-Seq platform for non-invasive identification of diverse hepatic molecular disruptions and for fibrosis staging with promising potential for clinical trials and clinical practice.</p>
Data from: Nut intake and non-alcoholic fatty liver disease risk
Abstract Objectives: Nut consumption has been associated with a lower risk of type 2 diabetes, metabolic syndrome, and insulin resistance. However, its effect on the risk of non-alcoholic fatty liver disease (NAFLD) is unknown. Therefore, we investigated the relationship between nut consumption and NAFLD risk. Setting and participants: We conducted a retrospective case-control study including 534 patients diagnosed with NAFLD and 534 controls matched by sex and age (± 5) from the Affiliated Nanping First Hospital of Fujian Medical University in China. Main outcome measures: Information on dietary intake was collected using a semi-quantitative food frequency questionnaires and nut consumption was calculated. Nut consumption was categorized using quartiles based on the distribution of daily nut intake of the controls. Binary logistic regression models were used to estimate odds ratio (ORs) and the 95% confidence intervals (CIs) for the association between nut consumption and NAFLD risk. Results: After adjusting for potential confounding variables, nut consumption was not associated with NAFLD risk in the overall sample. When the fully adjusted model was stratified by sex, a significant inverse association was found between high nut consumption and NAFLD only among the men in the highest quartile (OR = 0.43; 95% CI: 0.26–0.71; Ptrend = 0.01). The inverse association of nut consumption with NAFLD risk in men remained significant after controlling for other known or suspected risk factors for NAFLD. Conclusions: Diets with a higher intake of nuts may be associated with a decreased risk of NAFLD, particularly in men.
A Prospective/Retrospective, Observational Follow-up Study of Chronic Hepatitis B With Non-alcoholic Fatty Liver Disease.
ClinicalTrials.gov study NCT05255978. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease
ClinicalTrials.gov study NCT07180745. IPD Sharing: NO. Countries: 1. Publications: 0.
Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
ClinicalTrials.gov study NCT02927184. IPD Sharing: NO. Countries: 1. Publications: 0.
PolyCystic Ovary Syndrome as Suggested Risk Group for Non-Alcoholic Fatty Liver Disease
ClinicalTrials.gov study NCT07146815. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Effects of Dietary Intervention and Surgery on NAFLD (Non-Alcoholic Fatty Liver Disease)
ClinicalTrials.gov study NCT03186859. IPD Sharing: NO. Countries: 1. Publications: 0.
Effect of a Multi-ingredient on Visceral Adiposity and Non-alcoholic Fatty Liver Disease in Individuals With Abdominal Obesity
ClinicalTrials.gov study NCT05807204. IPD Sharing: NO. Countries: 1. Publications: 0.
To Explore the Effectiveness of Jing-Si Herbal Tea Against Non-alcoholic Fatty Liver Disease
ClinicalTrials.gov study NCT05858138. IPD Sharing: NO. Countries: 1. Publications: 0.
Obstructive Sleep Apnea and Non-alcoholic Fatty Liver Disease
ClinicalTrials.gov study NCT03373643. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Study on the Correlation Between Fat Soluble Vitamins and Non-alcoholic Fatty Liver Disease
ClinicalTrials.gov study NCT06512701. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.